Tumour response in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors – assessment of intra-tumour heterogeneity

BMC Medicine

Commentary

Jens Bedke¹  Viktoria Stühler¹ 

[1] Department of Urology, Eberhard Karls University, Hoppe-Seyler- Strasse 3, 72076, Tübingen, Germany;

关键词: Metastatic clear cell renal carcinoma;    Intra-tumour heterogeneity;    Response pattern;    Tyrosine kinase treatment;    RECIST criteria;    Pseudoprogression;   

DOI  :  10.1186/s12916-016-0754-8

 received in 2016-11-15, accepted in 2016-11-23,  发布年份 2016

来源: Springer

【 摘 要 】

Intra-tumour heterogeneity is a common molecular phenomenon in metastatic clear cell renal carcinoma (mRCC), representing the genetic complexity of a tumour with multiple metastatic sites. The present commentary discusses the observed phenomena of phenotypic intra-tumour heterogeneity in mRCC patients treated with the tyrosine kinase inhibitors sunitinib or pazopanib. Here, drug response can be different on the level of each evaluated metastasis in the individual patient. This questions the currently used radiologic staging systems of RECIST criteria and demands for a modification of radiologic response assessment with the consequence of a patient-tailored therapy in the clinical setting.Please see related article: http://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-016-0729-9.

【 授权许可】

CC BY   
© The Author(s). 2016